Clinical Trial Radar

Name: Cervical Plexus Hydrodissection With D5W for PTSD Versus Delayed Treatment/Usual Care
Creator: Dr. Dean Reeves Clinic
Published: 2020-06-09
License: https://www.clinicaltrials.gov/about-site/terms-conditions#availability

beta

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Clinical Trial NCT04421573 for PTSD is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.

One study matched filter criteria

Card View

Cervical Plexus Hydrodissection With D5W for PTSD 24 Randomized Observational

Recruiting

Clinical Trial NCT04421573 is an interventional study for PTSD that is recruiting. It started on July 10, 2023 with plans to enroll 24 participants. Led by Dr. Dean Reeves Clinic, it is expected to complete by October 1, 2027. The latest data from ClinicalTrials.gov was last updated on January 27, 2026.

Brief Summary

PTSD is a chronic mental health condition that drastically reduces an individual's quality of life Dextrose injection with a small needle has been used for chronic pain patients and observational results have shown it to be effective in reducing anxiety, brain fog, and depression in patients with PTSD. This randomized trial will compare dextrose injection with a delayed/usual treatment control.

Detailed Description

PTSD is a well-recognized debilitating mental health condition associated with previous trauma exposure. It is part of the DSM-5 Trauma and Stressor related disorders category. Treatments for PTSD normally involve a multi-disciplinary approach. First-line treatments include psychotherapy and serotonergic reuptake inhibitors. Many patients fail pharmacotherapy and psychotherapy. Unilateral stellate ganglion block perf...Show More

Official Title

Cervical Plexus Hydrodissection With D5W for PTSD Versus Delayed Treatment/Usual Care

Conditions

PTSD

Publications

Rae Olmsted KL, Bartoszek M, Mulvaney S, McLean B, Turabi A, Young R, Kim E, Vandermaas-Peeler R, Morgan JK, Constantinescu O, Kane S, Nguyen C, Hirsch S, Munoz B, Wallace D, Croxford J, Lynch JH, White R, Walters BB. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder...

Other Study IDs

DextrosePTSD1

NCT ID Number

NCT04421573

Start Date (Actual)

2023-07-10

Last Update Posted

2026-01-27

Completion Date (Estimated)

2027-10-01

Enrollment (Estimated)

Study Type

Interventional

PHASE

N/A

Status

Recruiting

Keywords

Dextrose
Hydrodissection
Cervical Plexus

Primary Purpose

Treatment

Design Allocation

Randomized

Interventional Model

Parallel

Masking

None (Open Label)

Arms / Interventions

Participant Group/Arm	Intervention/Treatment
ExperimentalBCPHD-D5W with usual care Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks. All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.	BCPHD with D5W D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
Active ComparatorWaiting period with usual care All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.	Waiting period with usual care Same as previous group description

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Consent rate	Percentage consent rate for qualifying participants	3 months
Data Capture rate	Percentage data capture	3 months
Satisfaction rating	Satisfaction with treatment outcome as measured by a 0-10 Numerical Rating Scale (NRS)	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PCL-C Score	Improvement (reduction) in PTSD check list for civilians	3 months
HADS scale	Improvement in the Hospital Anxiety and Depression Scale	3 months
EuroQOL 0-100	0-100 rating of quality of life	3 months

Participation Assistant

Eligibility Criteria

Eligible Ages

Adult, Older Adult

Minimum Age

19 Years

Eligible Sexes

All

Not involved in another study of PTSD treatment
Reliable transportation
Comfortable with computers
Tried 2 or more medications for treatment of PTSD symptoms
Tried 2 or more non-medication treatments for PTSD symptom
No known life-threatening illness
Not taking daily narcotics
Not having 3or more alcoholic drinks on an average day
No active suicidal plans
No major surgery plans
No major life stress that might interfere with completing study
Symptoms for more than 1 year
Not planning to move for next 18 months.
Living within an hour of Portlland, OR, Madison, WI, or Lexington, KY
Wiling to provide 2 email and 2 phone contact methods
Willing to answer questions on multiple occasions over the course of a year.
Willing to be assigned to 3 months of usual care treatment
No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder.
No severe needle phobia
Chronic pain ≤ 5/10
PCL-C score ≥ 50

None separate from inclusion criteria

Dr. Dean Reeves Clinic

🏛️Paul Johnson, D.O...

Study Responsible Party

Dr. Dean Reeves, Principal Investigator, Principal Investigator, Dr. Dean Reeves Clinic

Study Central Contact

Contact: Kenneth D Reeves, M.D., 9133621600, [email protected]

4 Study Locations in 1 Countries

United States

Kentucky

Danesh Mazloomdoost, Lexington, Kentucky, 40509, United States

Danesh Mazloomdoost, MD, Contact, 859-275-4878, [email protected]

Recruiting

Oregon

Paul W. Johnson, D.O., Clinic., Portland, Oregon, 87213, United States

Paul W. Johnson, D.O., Contact, [email protected]

Recruiting

NW Regen, Tigard, Oregon, 97224, United States

Ryan R Wood, D.C., N.D., Contact, [email protected]

Recruiting

Wisconsin

Eric Phillippi M.D. Clinic, Madison, Wisconsin, 53719, United States

Eric Phillippi, M.D., Contact, [email protected]

Recruiting

Cervical Plexus Hydrodissection With D5W for PTSD 24 Randomized Observational

Inclusion Criteria

Exclusion Criteria